Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur
40,19
EUR
+0,41 % +0,17
22:23:33 Uhr,
Baader Bank
Knock-Outs auf Novo Nordisk
Werbung
Diese Werbung richtet sich nur an Personen mit Wohn-/Geschäftssitz in Deutschland. Der jeweilige Basisprospekt, etwaige Nachträge, die Endgültigen Bedingungen sowie das maßgebliche Basisinformationsblatt sind auf www.dzbank-wertpapiere.de veröffentlicht. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Kommentare 50.299
R
RobRob23,
3. Apr 11:37 Uhr
2
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1 In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
Wurde gestern von Novo rausgegebene wignifikant besserer Gewichtsverlust als bei der Pille von Lilly
RobRob23,
3. Apr 11:36 Uhr
2
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1
Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1
In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
T
Tsindu12,
3. Apr 10:58 Uhr
0
Deutsche Privatanleger die auf einen Boden hoffen
csl1234,
3. Apr 9:50 Uhr
2
Was noch interessant ist: Novo hat auf der Hauptversammlung die Ermächtigung erhalten bis 2027 bis zu 10% der Aktien zurück zu kaufen. Doustdar nannte 2026 das Jahr der Transformaton. Wenn Novo nicht weiß, wann Sie Aktien kaufen sollen, wer dann?
McLovin09,
3. Apr 9:43 Uhr
0
An interesting pattern in $NVO price action. Just data. You decide what it means.
During active buyback (Oct-Dec 2025):
October: $59 → $49. Down 16%.
November: $49 → $49. Flat.
December: $48 → $51. Up 5%.
During blackout / no buyback (Jan 2026):
January: $52 → $64. Up 13%.
The stock ROSE 13% the month Novo stopped buying.
Then on February 4 — the FIRST DAY of the new buyback programme — Novo published guidance of -5% to -13% sales decline.
The stock crashed 15% that day. From $59 to $43.
The new DKK 3.8B buyback tranche started buying immediately. At $43. Then $38. Then $36.
Average buyback prices tell the story:
Feb 4-27: DKK 286.95 per share
Feb 4 - Mar 20: DKK 266.53
Feb 4 - Mar 27: DKK 261.91
Each week, the average price drops. More shares per DKK spent.
9.16 million B shares acquired at an average of DKK 261.91. That's 20% below where the stock traded during the January blackout.
Now the timeline repeats:
~April 6: Blackout begins (30 days before Q1 results May 6)
April 6 - May 6: No buyback. No buying pressure. No selling pressure.
May 6: Q1 results. 1.2M Wegovy pill prescriptions vs -13% guidance.
If January's pattern repeats, the stock rises during the blackout.
If the guidance surprise is positive, May 6 could be significant.
I'm not drawing conclusions. I'm showing the pattern.
The data is public. The filings are public. The prices are public.
Follow the pattern. Follow the filings.
$NVO #GLP1 #SNAC #buyback
csl1234,
3. Apr 9:31 Uhr
0
Jamey Millar, neuer Executive VP, Novo US *** https://www.instagram.com/reel/DWpZauDjib8/?igsh=dnIzZnc4eGd6dm00
csl1234,
3. Apr 7:39 Uhr
0
Massenmarkt in Indien?
***
https://www.reuters.com/business/healthcare-pharmaceuticals/indias-mounjaro-brides-weight-loss-injections-become-part-pre-wedding-2026-04-03/
J
T
Stonksstocks,
3. Apr 2:13 Uhr
0
US imposes 100% pharma tariff, strengthens metal duties - baha.com https://share.google/wY5KWBj9XpYHqtYQ2
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Novo Nordisk nach Split | ||
| 2 | Novo Nordisk |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Enovix Corporation Hauptdiskussion | -9,88 % | |
| 2 | PLUG POWER Hauptdiskussion | +9,43 % | |
| 3 | RHEINMETALL Hauptdiskussion | -3,61 % | |
| 4 | DAX Hauptdiskussion | +0,67 % | |
| 5 | GAMESTOP Hauptdiskussion | -1,18 % | |
| 6 | Aktuelles zu Almonty Industries | -11,18 % | |
| 7 | für alle, die es ehrlich meinen beim Traden. | ||
| 8 | SAP Hauptdiskussion | -3,63 % | |
| 9 | Trading- und Aktien-Chat | ||
| 10 | CoinBase (Future ExChange) | -2,83 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Enovix Corporation Hauptdiskussion | -10,08 % | |
| 2 | PLUG POWER Hauptdiskussion | +9,02 % | |
| 3 | RHEINMETALL Hauptdiskussion | -3,61 % | |
| 4 | GAMESTOP Hauptdiskussion | -1,23 % | |
| 5 | Aktuelles zu Almonty Industries | -11,18 % | |
| 6 | SAP Hauptdiskussion | -3,38 % | |
| 7 | CoinBase (Future ExChange) | -2,83 % | |
| 8 | YNVISIBLE INTERACTIVE Hauptdiskussion | -4,17 % | |
| 9 | Investmentchancen | -2,52 % | |
| 10 | Diginex nach RS - sachliche Diskussion | -2,31 % | Alle Diskussionen |